Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
Go back to Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)| (NASDAQ: RCKT) | Delayed: 3.46 +0.11 (3.28%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.35 | 52 Week High | $ | |||
| Open | $3.38 | 52 Week Low | $ | |||
| Day High | $3.50 | P/E | N/A | |||
| Day Low | $3.35 | EPS | $ | |||
| Volume | 2,427,364 | |||||
